AI-designed CRISPR enzymes expand gene-editing toolkit
This digest was compiled by AI from multiple sources — links to the originals are below.
Researchers used artificial intelligence to design functional CRISPR enzymes not found in nature, according to a study published in Nature on 16 July 2026. The AI-generated 'molecular scissors' can target DNA sequences inaccessible to natural CRISPR systems. The approach could dramatically broaden the scope of gene editing for research and therapy.
AI-Designed Enzymes
The study, published in Nature on 16 July 2026, describes the use of a deep-learning model to generate novel CRISPR-associated proteins. The AI designed enzymes that recognize and cut DNA at specific sequences not targeted by any known natural Cas proteins. The team validated several of these synthetic enzymes in human cell cultures, achieving editing efficiencies comparable to natural CRISPR systems.
Expanded Targeting Range
Natural CRISPR systems are limited by the availability of protospacer adjacent motif (PAM) sequences required for DNA binding. The AI-designed enzymes recognize a broader set of PAMs, including those found in previously inaccessible genomic regions. This expands the number of potential therapeutic targets, particularly in complex diseases like cancer and genetic disorders.
Implications for Gene Therapy
The ability to design custom CRISPR enzymes on demand could accelerate development of gene therapies for conditions with few treatment options. Researchers note that the AI approach reduces the need for laborious experimental screening of natural variants. However, the synthetic enzymes must still undergo rigorous safety testing before clinical use.
What's Next
The research team plans to further optimize the AI-designed enzymes for in vivo applications and to explore delivery methods for therapeutic use. It remains unclear how regulatory agencies will evaluate gene-editing tools derived from artificial intelligence.
2 sources
AI-designed CRISPR enzymes expand gene-editing toolkit
